Gordian Screens 1,327 Targets In Vivo, Accelerating Drug Discovery
juanbenet · x · 2026-08-27
Juan Benet shared a progress report from Gordian Biotechnology. Their drug discovery machine has captured the effects of 1,327 targets in living diseased tissue across six disease areas, nearly matching the total reported by the global biomedical community over the past 20 years.
- Coverage: 352 in MASH, 304 in obesity, 290 in heart failure, 168 in osteoarthritis, 203 in PPF, with expansion into chronic kidney disease.
- Method: Uses Mosaic Screening to uniquely test the causal effects of hundreds of barcoded perturbations directly in vivo.
- Advantage: Generates evidence first before picking winners, rather than betting upfront. This approach is set to shave years off the drug discovery timeline.
More from Research
- TIDES Dataset: Longitudinal Bilingual Record of 12 Teams' Collaboration — josephseering · 2026-08-27
- Kyoto U's MemUse: Natural Integration Outperforms QA in Evaluating Conversational Memory — Kyoto-University · 2026-08-27
- GPT-5.6 Builds New Kernel, Achieving 9.7x Speedup on TPU — HuaxiuYaoML · 2026-08-27
- RSI-Exam Benchmark Launches to Test AI Recursive Self-Improvement — HuaxiuYaoML · 2026-08-27
- Discussion on Multi-Agent Reward Schemes and Convergence — jessi_cata · 2026-08-27
- Why scaling LLMs won't lead to real agency: A 3-tier Embodied AI architecture — Far-Start-1789 · 2026-08-27